100 results about "Acquired resistance" patented technology

The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and / or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and / or tumour resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour.

The invention provides dilute and concentrated, aqueous, pharmaceutical compositions comprising gamma-hydroxybutyric acid or pharmaceutically acceptable salts thereof; gamma-butyryl lactone; 1,4-butanediol; 4-hydroxyl pentanoic acid or pharmaceutically acceptable salts thereof; 4-hydroxyl pentanoic acid lactone, or combinations thereof, and a coloring agent and / or flavoring agent that is useful in preventing sexual assault or date rape. Methods of treating conditions responsive to the administration of gamma-hydroxyl butyric acid and / or its pharmaceutically acceptable salts; gamma-butyryl lactone; 1,4-butanediol; 4-hydroxyl pentanoic acid and / or its pharmaceutically acceptable salts; and 4-hydroxyl pentanoic acid lactone are also described. The invention provides methods for treating patients with acquired resistance to GABAnergic agents.

The invention relates to a method for measuring planta pressure for rehabilitation therapy. The method is characterized in that thin film piezoresistive type pressure sensors are adopted to be placed on planta pressure points in left and right sock linings, each sock lining is of a three layer structure, and the top layer and the bottom layer are fiber layers; the thin film piezoresistive type pressure sensors are tightly adhered to and fixed on the bottom layers closely, are fixedly connected with the fibers at the top layers through soft salient points, and transmits the acquired resistance signals corresponding to the pressure to two signal processing transmitters which are corresponding to the pressure sensors of the left and right sock linings, the resistance signals are subjected to resistance-voltage conversion and wave filtration and then are output to two corresponding micro processors so as to be subjected to AD (analog-to-digital) conversion respectively; data acquired from two feet are merged into a data packet and is transmitted to a receiver; the receiver transmits the data of the left and right feet to a PC (personal computer) through a USB (universal serial bus); and the PC reads the data through the triggering of a timing device, and unpacks the data packet, and signal processing and three dimensional display are carried out through software.

The invention provides a measurement system and measurement method utilizing non-freezing model ice to obtain the ship model resistance in trash ice. First, by selecting non-freezing model ice from a conventional towing pool to replace frozen model ice in an ice pool, so that the towing pool without a low temperature environment is equipped with the condition of simulating ice trash working conditions; and then a unique buoy fence structure is designed on the surface of the towing pool to achieve simulation of an ice trash channel, and a force cell is used to realize measurement of the ship model resistance at different speeds. In addition, the invention adopts the means of firstly measuring the resistance of the open water and measuring the resistance at a very low speed (0.02m / s) under the floating ice condition, elements such as the open water resistance, the floating ice resistance and the clear ice resistance are separated, and the resistance performance of a corresponding ship model and a real boat in the working condition of trash ice is forecast. The measurement system and measurement method of the invention provides a new idea for measurement of the ship model resistance in the trash ice in a condition that now ice pool facilities in china are not perfect.

The disclosure provides compositions and methods for detecting and predicting acquired resistance to anti-EGFR treatment in colorectal cancers. Also provided are compositions and methods of preventing, reversing or delaying the acquired resistance. The present disclosure also provides kits for use in the methods described herein.

The invention discloses a distributed power generation system and island detection device thereof. The distributed power generation system comprises a grid-connected current converter, an input source providing the electric energy for the grid-connected current converter, a grid-connected switch that is connected between the output side of the grid-connected current converter and the grid, a point of common coupling that is located between the grid-connected current converter and the grid-connected switch, a load connected to the point of common coupling, a capacitor module consisting of a plurality of capacitors, a switching module and an island detection device; wherein one end of the switching module is connected with the capacitor module, the other end of the switching module is connected with the point of common coupling; when the switching module is closed, the capacitor module is connected with the point of common coupling; when the switching module is opened, the capacitor module is disconnected with the point of common coupling; the island detection device is used to acquire the resistance value at the point of common coupling and compare the acquired value with the resistance threshold value. If the acquired resistance value is larger than the resistance threshold value and the duration thereof exceeds the preset time length, then it is determined that the island effect occurs.

The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof: [where R1 represents hydrogen atom or lower alkoxy group; R2 represents hydrogen atom, lower alkoxy group, optionally substituted phenyl group, (where R3 represents acyl group); X represents —CO— or —CH2—; and n-represents 1 or 2], as drugs for overcoming a resistance to anticancer drugs or drugs for enhancing an effect of anticancer drugs. The compounds represented by the general formula [1] have not only a function of overcoming the resistance to various anticancer drugs but also a function of enhancing the effect of various anticancer drugs to anticancer-drug sensitive cells. Thus, these compounds have excellent effects on resistant cells and also on sensitive cells, and in particular effective in the treatment of a cancer having an acquired resistance to an anticancer drug.

Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1](in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and / or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effect ive amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and / or tumour resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour.

The invention belongs to the field of temperature measurement, and provides a high-precision multi-point temperature measurement system and a temperature calibration method based on a thermal resistor. The system comprises a chain type temperature sensor, an analog switch circuit, a signal acquisition unit, a single-chip microcomputer and a display unit. The chain type temperature sensor comprisesa plurality of thermal resistor temperature-sensitive elements, and the control end of the analog switch circuit is connected with the output end of the single-chip microcomputer; the signal acquisition unit is composed of an analog-digital conversion chip, the signal output ends of the thermal resistor temperature-sensitive elements are connected with the input end of the analog-digital conversion chip through the analog switch circuit; the detected voltage values of the thermal resistor temperature-sensitive elements are converted into resistance values R to be stored in the analog-to-digital conversion chip, and the single-chip microcomputer can obtain the acquired resistance value R of the thermal resistor through SPI communication; on the basis of the temperature calibration method obtained through analysis and calculation, data processing is achieved in the single-chip microcomputer, and an accurate temperature value is obtained. According to the system and the method, the temperature measurement precision in a low-temperature environment is effectively improved, and the system and the method can be widely applied to the field of environmental research.

A compound or its pharmaceutically acceptable salt represented by the following formula:The invention is a carbapenem compound which has a potent antibacterial activity over a broad range of Gram negative and Gram positive bacteria, especially penicillin-resistant Streptococcus pneumoniae (PRSP) which has been isolated at an elevated frequency in recent years and thus causes a serious clinical problem, and Haemophilus influenzae which has acquired resistance against the existing β-lactam antibiotics over a wide scope due to penicillin-binding protein (PBP) mutations such as β-lactamase non-producing ampicillin-resistant (BLNAR) Haemophilus influenzae, and has excellent oral absorbability.

The invention relates to application of paclitaxel in preparation of medicament for treatment of non small cell lung cancer EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) resistance. Lung cancer ranks the first in cancer incidence and mortality all over the world. Curative effects of Gefitinib and Erlotinib in NSCLC are often limited by acquired resistance, and currently known main mechanism of acquired resistance is due to mutation of second generation of EGFRT790M and acquired amplification of MET gene. The invention shows that when EGFR-TKI acquired resistance appears, paclitaxel may reverse the resistance. That is to say, non small cell lung cancer patients who generate acquired resistance from Erlotinib / Gefitinib treatment can reconsider the use of Erlotinib / Gefitinib treatment after chemotherapy with paclitaxel, so as to make the erlotinib / gefitinib continue to function; meanwhile, paclitaxel may also inhibit tumor, and thus play rotary resistance and synergism.

The invention relates to the establishment of a transgenic system of Populus chinensis and the propagation method of the transgenic plant, which relates to the establishment of the transgenic system and the propagation method of the transgenic plant. System establishment: obtain tissue culture seedlings; activate engineering bacteria containing LbDREB gene and transform exogenous genes; obtain resistant buds after degerming; resistant buds take root and transplant; Positive plants are complete. Propagation: The transgenic regenerated plants of Populus chinensis obtained by establishing the transgenic system of Populus chinensis were differentiated and cultured to obtain tissue culture seedlings; PCR and RT-PCR were performed to detect positive roots, stems and leaves; 3. Repeat operation 2 times and you are done. The present invention can realize the rapid cultivation of transgenic Populus chinensis, and lays the foundation for the development of fine varieties of Populus chinensis; the produced offspring have good genetic stability, and are useful for realizing large-scale, short-period, high reproduction rate and low nutrient density of transgenic Populus chinensis seedlings. The cost of factory production is of great significance.

The invention provides a pesticide water solution and a preparing method and application thereof. The pesticide water solution comprises the following raw materials: 0.1-20% of amino-oligosaccharin, 0.1-20% of tetramycin, 1.0-10% of a wetting dispersant, 1.0-10% of penetrant, 3.0-8.0% of an antifreezing agent, 0.1-5% of an antifoaming agent and the rest of water. The ingredients are uniformly mixed into a transparent brown according to the requirements of a formula, thereby obtaining the pesticide water solution. The biological pesticide amino-oligosaccharin is used as the signal molecule (elicitor) of the pesticide water solution, a plant is rapidly and effectively induced to produce defense reaction, the SAR (System Acquired Resistance) of the plant is activated, and a broad spectrum effect of preventing and treating bacteria and fungi is realized through the combination of the biological pesticide tetramycin. The amino-oligosaccharin and the tetramycin are scientifically compounded so as to increase the effect of each other in a synergistic way. The pesticide water solution has the advantages of rapid effect taking, long lasting period, broad sterilizing spectra, no toxicity, no residue and the like. The preparing method is simple, has a wide range of applications and is suitable for the requirements of large-scale industrial production.

A promotor induced by the acquired resistance inducter of plant system and its application are disclosed. The promoter comes from the gene of Arabidoposis, which is sensitive to PB2 and its relative compound. The nucleic acid sequence of desired target product gene is combined with said promotor fragment to obtain recombinant DNA, which is used to transform plant to obtain a new transgenic plant, in which the expression of target gene in recombinant DNA is regulated by the chemical inducing of PBZ.

A compound represented by the general formula (I) or a salt thereof having a potent antibacterial activity against bacteria that have acquired resistance to quinolones, and a medicament for prophylactic and / or therapeutic treatment of an infectious disease containing the compound or a salt thereof as an active ingredient, as well as a medicament for prophylactic and / or therapeutic treatment of an infectious disease containing a combination of the compound or a salt thereof, and a quinolone.

The invention provides a novel electric nondestructive anchor rod length measuring method and device. The novel electric nondestructive measuring method includes that a measuring hole is drilled when measuring and connected with the anchor rod, a direct-current stabilized power supply, a resistance test instrument and a metal ball probe in sequence, the direct-current stabilized power supply outputs constant direct-current voltage to detect resistance values of loops; the metal ball probe is moved downwardly along the measuring hole to measure the resistance values of the loops secondarily; the rest is done in the same manner till the metal ball probe moves deep to the bottom of the measuring hole; a resistance-depth curve is drawn according to multiple acquired resistance values, and actual embedment length of the anchor rod is judged according to increasing turning points appeared in the resistance-depth curve. In the measuring method, the bottom of the anchor rod can be measured by utilizing direct-current electric fields generated from the a metal anchor rod and resistance change of the loops by adjusting relative position of point electrodes and anchor rod electrodes. The novel electric nondestructive anchor rod length measuring device is simple in overall structure, convenient to operate, and applicable to measurement of the anchor rods in surrounding rocks under poor conditions.

The present invention relates to a method of treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and / or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and / or tumor resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor.

This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer. It elevates the level of an antiangiogenic drug produced by chromosome 21 preferably Endostatin in plasma preferably at least one day prior to surgery and kept at that high level preferably indefinitely. The therapy specifically excludes drugs that significantly inhibit the VEGF pathway since that is important for wound healing. This method will prevent results of surgery from stimulating tumor growth and angiogenesis of micrometastatic disease that is much easier to prevent than control after the fact. This can be done indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies.

The invention provides a semiconductor structure and a method for acquiring the resistance of a water-level bonding structure by adopting the same. The acquiring method comprises the steps of measuring the resistances of two wafers before and after bonding, and acquiring the resistance of a water-level bonding structure according to the series-parallel relationship between the resistances of the two wafers before and after bonding and the resistance of the water-level bonding structure. The acquiring method does not rely on the experience values of the resistances of a pad, a metal interconnect and a conductive plug for connecting the pad and the metal interconnect, so that the acquired resistance of the water-level bonding structure is accurate.

The present invention relates to antiviral drug susceptibility and resistance assays for identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), and to monitoring the clinical progression of HIV infection and Modes and methods of HIV infection response to antiretroviral therapy, in particular nucleoside reverse transcriptase inhibitor therapy using phenotypic sensitivity analysis and genotypic analysis.

Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.

Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.

The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC / Dkk-3 DNA as an active ingredient and having effects of potentiating an anticancer drug for cancer cells having anticancer drug resistance.

A compound or its pharmaceutically acceptable salt represented by the following formula: The invention is a carbapenem compound which has a potent antibacterial activity over a broad range of Gram negative and Gram positive bacteria, especially penicillin-resistant Streptococcus pneumoniae (PRSP) which has been isolated at an elevated frequency in recent years and thus causes a serious clinical problem, and Haemophilus influenzae which has acquired resistance against the existing β-lactam antibiotics over a wide scope due to penicillin-binding protein (PBP) mutations such as β-lactamase non-producing ampicillin-resistant (BLNAR) Haemophilus influenzae, and has excellent oral absorbability.

The invention provides an antistatic wrist band monitor. The monitor comprises a wrist band contact sensing module, a comparison module and a control module. The wrist band contact sensing module is used for acquiring the capacitance value between an antistatic wrist band and the skin, and the resistance value between the antistatic wrist band and the ground. The comparison module is electrically connected with the wrist band contact sensing module and is used for comparing whether the acquired capacitance value and the acquired resistance value are in set values respectively. The control module is electrically connected with the comparison module and used for generating a control signal when judging that the antistatic wrist band is abnormally worn according to results given by the comparison module. Thus, real-time monitoring on working states of the antistatic wrist band is achieved.

Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1](in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

Methods and compositions are described to treat a cancer having a specific oncogenic driving mutation by administering a CDK4 / 6 inhibitor in combination with an additional kinase inhibitor, wherein the specific combination provides advantageous or synergistic inhibitory activity, delays acquired resistance to the additional kinase inhibitor, and / or extends the efficacy of the kinase inhibitor.

An antibacterial agent comprising a compound represented by the following general formula (I), which can exhibit potent antibacterial activity against bacteria that have acquired resistance to quinolones (in the formula, R1 and R4 represents hydrogen atom, hydroxyl group, or a lower alkoxy group; R2 and R3 represents hydrogen atom or hydroxyl group; W represents hydrogen atom, a lower cyclic alkyl group, or a lower alkoxy group; R1′ and R5′ represents hydrogen atom; R2′ and R3′ represents hydrogen atom, hydroxyl group, or a lower alkoxy group; and R4′ represents hydrogen atom or hydroxyl group).